[{"data":1,"prerenderedAt":-1},["ShallowReactive",2],{"health-studies-list:{\"conditionNormalized\":\"invasive-fungal-infections\",\"overallStatus\":[\"RECRUITING\",\"AVAILABLE\",\"NOT_YET_RECRUITING\"],\"orderBy\":\"LastUpdateSubmitDate:desc\",\"size\":25,\"offset\":0}":3,"health-study-condition:invasive-fungal-infections":34},{"pageToken":4,"total":5,"offset":6,"count":5,"results":7},null,11,0,[8,54,79,105,130,154,180,200,227,252,282],{"id":9,"slug":10,"hasResults":11,"nctId":12,"briefTitle":13,"officialTitle":14,"acronym":4,"eligibilityCriteria":15,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":18,"enrollmentInfo":19,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":24,"conditions":25,"keywords":35,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":42,"lastUpdatePostDateStruct":43,"startDateStruct":46,"completionDateStruct":48,"leadSponsor":50,"locationsCount":53},"100651557","low-dose-liposomal-amphotericin-b-for-antifungal-prophylaxis-in-prolonged-neutropenia-patients-100651557",false,"NCT07763054","Low-dose Liposomal Amphotericin B for Antifungal Prophylaxis in Prolonged Neutropenia Patients","Evaluation of Low-Dose Liposomal Amphotericin B for Prophylaxis of Invasive Fungal Infections in Patients With Prolonged Neutropenia: A Clinical Study","Inclusion Criteria:\n\n* Age 18 to 75 years (inclusive), both sexes.\n* Meets NCCN 2025 V1 guideline criteria for high-risk invasive fungal disease, including allogeneic hematopoietic stem cell transplantation, autologous hematopoietic cell transplantation with mucosal damage, acute leukemia, grade 3\u002F4 graft-versus-host disease, myelodysplastic syndrome, lymphoma, multiple myeloma, chronic lymphocytic leukemia, treatment with purine analogues (fludarabine, clofarabine, nelarabine), chimeric antigen receptor (CAR) T-cell therapy, alemtuzumab therapy, with expected neutropenia \\>7 days and accompanied by agranulocytosis.\n\nNote: Agranulocytosis is defined as absolute neutrophil count ≤0.5×10\\^9\u002FL, or absolute neutrophil count ≤1×10\\^9\u002FL with expected decline to ≤0.5×10\\^9\u002FL within 48 hours.\n\n* Assessed by the study physician as having high-risk for invasive fungal infection, intolerant or unable to use other antifungal agents due to toxicity or other reasons, and the treating physician has independently decided in routine clinical practice to initiate liposomal amphotericin B for antifungal prophylaxis for 3-5 days, with the selected dosage regimen of 50 mg\u002Fday, intravenous, once daily.\n* Patient or legally authorized representative has voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Allergy to any component of liposomal amphotericin B, or development of serious adverse events during the initial 3-5 days of prophylactic use.\n* Prior history of proven or probable invasive fungal disease (IFD).\n* Presence of pneumonia, unexplained fever, or clinical\u002Fimaging evidence suggestive of or diagnosed as fungal infection during screening.\n* Clinically significant hypokalemia (defined as serum potassium \\\u003C3.2 mmol\u002FL, or below the lower limit of normal while receiving digitalis therapy) that cannot be corrected before starting trial treatment.\n* Hepatic dysfunction with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥5× upper limit of normal (ULN), or total bilirubin ≥3× ULN.\n* Renal impairment requiring or currently undergoing hemodialysis or peritoneal dialysis.\n* New York Heart Association (NYHA) Class III\u002FIV heart failure.\n* Positive for human immunodeficiency virus (HIV) antibody or Treponema pallidum hemagglutination assay (TPHA).\n* Expected survival \\\u003C3 months.\n* Pregnant or breastfeeding women, or women of childbearing potential who are not using contraception and planning pregnancy.\n* Any other condition that the investigator considers inappropriate for participation in the clinical trial.","ALL","18 Years","75 Years",{"count":20,"type":21},30,"ESTIMATED","7 Days","OBSERVATIONAL","This is a single-center, single-arm, observational clinical study evaluating the efficacy and safety of low-dose liposomal amphotericin B (50 mg\u002Fday, intravenous, once daily) for the prevention of invasive fungal infections in adult patients (aged 18-75 years) with hematological malignancies who develop prolonged neutropenia (absolute neutrophil count ≤0.5×10\\^9\u002FL, expected to last \\>7 days) and are at high risk for invasive fungal disease. Participants are those who, per the treating physician's routine clinical decision, have been initiated on liposomal amphotericin B prophylaxis at 50 mg\u002Fday due to intolerance or toxicity to other antifungal agents. The primary outcome is the incidence of proven or probable invasive fungal disease. Secondary outcomes include incidence of pneumonia, persistent unexplained fever \\>4 days, use of additional systemic antifungal therapy, and adverse events. A total of 30 participants will be enrolled. Data will be collected at baseline, during treatment, and within 7 days after treatment completion.",[26,27,28,29,30,31,32,33,34],"Acute Myeloid Leukemia","Acute Lymphoblastic Leukemia","Myelodysplastic Syndrome","Lymphoma","Multiple Myeloma","Chronic Lymphocytic Leukemia","Neutropenia","ALLOGENEIC HEMATOPOIETIC STEM CELL TRANSPLANTATION","Invasive Fungal Infections",[36,37,38,39,40],"Liposomal Amphotericin B","Antifungal Prophylaxis","Invasive Fungal Disease","Prolonged Neutropenia","Hematological Malignancies","RECRUITING","2026-08-08",{"date":44,"type":45},"2026-08-13","ACTUAL",{"date":47,"type":45},"2025-08-01",{"date":49,"type":21},"2026-11-30",{"name":51,"class":52},"Haikou Affiliated Hospital of Central South University Xiangya School of Medicine","OTHER",1,{"id":55,"slug":56,"hasResults":11,"nctId":57,"briefTitle":58,"officialTitle":59,"acronym":4,"eligibilityCriteria":60,"healthyVolunteers":11,"sex":16,"minAge":61,"maxAge":62,"enrollmentInfo":63,"targetDuration":22,"studyType":23,"phases":4,"briefSummary":64,"conditions":65,"keywords":69,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":71,"lastUpdatePostDateStruct":72,"startDateStruct":74,"completionDateStruct":76,"leadSponsor":78,"locationsCount":53},"100648642","low-dose-liposomal-amphotericin-b-for-invasive-fungal-infection-prophylaxis-in-neutropenic-children-100648642","NCT07725263","Low-Dose Liposomal Amphotericin B for Invasive Fungal Infection Prophylaxis in Neutropenic Children","Evaluation of Efficacy and Safety of Low-Dose Liposomal Amphotericin B in Prophylaxis of Invasive Fungal Infections Among Children With Prolonged Neutropenia: A Clinical Study","Inclusion Criteria:\n\n* Age 3 to 17 years (inclusive), both sexes.\n* Meets NCCN 2025 V1 guideline criteria for high-risk invasive fungal disease, including allogeneic hematopoietic stem cell transplantation, autologous hematopoietic cell transplantation with mucosal damage, acute leukemia, grade 3\u002F4 graft-versus-host disease, myelodysplastic syndrome, lymphoma(a), multiple myeloma(a), chronic lymphocytic leukemia(a), treatment with purine analogues (fludarabine, clofarabine, nelarabine), chimeric antigen receptor (CAR) T-cell therapy, alemtuzumab therapy, with expected neutropenia \\>7 days(b) and accompanied by agranulocytosis.\n\nNote (a): For these heterogeneous diseases, myeloablative therapy must be met; if neutropenia \\>7 days is not met, the patient should be excluded.\n\nNote (b): Agranulocytosis is defined as absolute neutrophil count ≤0.5×10\\^9\u002FL, or absolute neutrophil count ≤1×10\\^9\u002FL with expected decline to ≤0.5×10\\^9\u002FL within 48 hours.\n\n* Assessed by the study physician as having high-risk for invasive fungal infection, intolerant or unable to use other antifungal agents due to toxicity or other reasons, and the treating physician has independently decided in routine clinical practice to initiate liposomal amphotericin B for antifungal prophylaxis for 3-5 days, with the selected dosage regimen of 1 mg\u002Fkg\u002Fday, intravenous, once daily.\n* Patient or legally authorized representative has voluntarily signed the informed consent form.\n\nExclusion Criteria:\n\n* Allergy to any component of liposomal amphotericin B, or development of serious adverse events during the initial 3-5 days of prophylactic use.\n* Prior history of proven or probable invasive fungal disease (IFD).\n* Presence of pneumonia, unexplained fever, or clinical\u002Fimaging evidence suggestive of or diagnosed as fungal infection during screening.\n* Clinically significant hypokalemia (defined as serum potassium \\\u003C3.2 mmol\u002FL, or below the lower limit of normal while receiving digitalis therapy) that cannot be corrected before starting trial treatment.\n* Hepatic dysfunction with aspartate aminotransferase (AST) or alanine aminotransferase (ALT) ≥5× upper limit of normal (ULN), or total bilirubin ≥3× ULN.\n* Renal impairment requiring or currently undergoing hemodialysis or peritoneal dialysis.\n* New York Heart Association (NYHA) Class III\u002FIV heart failure.\n* Positive for human immunodeficiency virus (HIV) antibody or Treponema pallidum hemagglutination assay (TPHA).\n* Expected survival \\\u003C3 months.\n* Pregnant or breastfeeding women, or women of childbearing potential who are not using contraception and planning pregnancy.\n* Any other condition that the investigator considers inappropriate for participation in the clinical trial.","3 Years","17 Years",{"count":20,"type":21},"This is a single-center, single-arm, observational clinical study evaluating the efficacy and safety of low-dose liposomal amphotericin B (1 mg\u002Fkg\u002Fday, intravenous, once daily) for the prevention of invasive fungal infections in children aged 3-17 years with hematological malignancies who develop prolonged neutropenia (absolute neutrophil count ≤ 0.5×10\\^9\u002FL, expected to last \\> 7 days) and are at high risk for invasive fungal disease. Participants are those who, per the treating physician's routine clinical decision, have been initiated on liposomal amphotericin B prophylaxis at 1 mg\u002Fkg\u002Fday due to intolerance or toxicity to other antifungal agents. The primary outcome is the incidence of proven or probable invasive fungal disease. Secondary outcomes include incidence of pneumonia, persistent unexplained fever \\>4 days, use of additional systemic antifungal therapy, and adverse events. A total of 30 participants will be enrolled. Data will be collected at baseline, during treatment, and within 7 days after treatment completion.",[66,67,32,34,68],"Thalassemia","Hematopoietic Stem Cell Transplantation","Graft vs Host Disease",[66,70,37,36,38,32],"Allogeneic Hematopoietic Stem Cell Transplantation","2026-07-23",{"date":73,"type":45},"2026-07-24",{"date":75,"type":45},"2026-02-01",{"date":77,"type":21},"2027-03-31",{"name":51,"class":52},{"id":80,"slug":81,"hasResults":11,"nctId":82,"briefTitle":83,"officialTitle":84,"acronym":4,"eligibilityCriteria":85,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":86,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":88,"conditions":89,"keywords":90,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":96,"lastUpdatePostDateStruct":97,"startDateStruct":99,"completionDateStruct":101,"leadSponsor":103,"locationsCount":4},"100633912","study-on-the-pharmacokinetic-characteristics-of-liposomal-amphotericin-b-in-patients-with-invasive-fungal-infections-undergoing-plasma-exchange-therapy-100633912","NCT07532850","Study on the Pharmacokinetic Characteristics of Liposomal Amphotericin B in Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy","Study on the Pharmacokinetic Characteristics, Safety, and Efficacy of Liposomal Amphotericin B in Critically Ill Patients With Invasive Fungal Infections Undergoing Plasma Exchange Therapy","Inclusion Criteria:\n\nAge ≥ 18 years old, gender not limited; According to \\\u003C The Chinese guidelines for the diagnosis and treatment of invasive fungal disease in patients with hematological disorders and cancers (the 6th revision) \\>, the diagnosis is neutropenia with fever, possible, probable, and proven IFD invasive fungal disease;\n\n* Currently receiving treatment with liposomal amphotericin B;\n* Undertaking plasma exchange support therapy;\n* Understand the research procedure and voluntarily sign a written informed consent form.\n\nExclusion Criteria:\n\nConfirmed patients with allergies\u002Frapid onset severe allergic reactions\u002Fintolerance to AmB Subjects who are known to be insensitive or resistant to amphotericin B treatment, such as those with invasive Aspergillus terreus and Aspergillus nidulans\n\n\\-",{"count":87,"type":21},10,"The goal of this prospective study is to describe the pharmacokinetic characteristics of liposomal amphotericin B during plasma exchange therapy for severe invasive fungal infections in Chinese patients, preliminarily explore the influencing factors of in vivo exposure variability of liposomal amphotericin B, and integrate the findings with efficacy and safety outcomes.\n\nThe main questions it aims to answer is: Clarifying the correlation between the concentration, efficacy, and safety of different forms of liposomal amphotericin B in a special population, explore the changes in drug concentration mediated by plasma exchange, elucidate the mechanism of individual differences in efficacy and the optimal dosage, in order to provide a basis for personalized treatment of liposomal amphotericin B.\n\nThe study plans to collect pharmacokinetic samples from 10 adult (aged ≥ 18 years) severe invasive fungal infection patients receive liposomal amphotericin B who undergo plasma exchange therapy.",[34],[91,92,93,94],"plasma exchange","invasive fungal infection","liposomal amphotericin B","pharmacokinetics","NOT_YET_RECRUITING","2026-04-13",{"date":98,"type":45},"2026-04-16",{"date":100,"type":21},"2026-03-30",{"date":102,"type":21},"2027-06-30",{"name":104,"class":52},"Institute of Hematology & Blood Diseases Hospital, China",{"id":106,"slug":107,"hasResults":11,"nctId":108,"briefTitle":109,"officialTitle":109,"acronym":110,"eligibilityCriteria":111,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":112,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":113,"conditions":114,"keywords":115,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":121,"lastUpdatePostDateStruct":122,"startDateStruct":124,"completionDateStruct":126,"leadSponsor":128,"locationsCount":53},"100524183","siderophore-labelled-positron-emission-tomography-for-correlating-invasive-fungal-infections-100524183","NCT06105411","Siderophore-labelled Positron Emission Tomography for Correlating Invasive Fungal InfeCtions","SPECIFIC","Inclusion Criteria:\n\n1. Patient has provided written informed consent\n2. Aged 18 years or older at written informed consent\n3. Within 2 weeks of proven or probable or possible invasive fungal infection (IFI) diagnosis as per EORTC criteria\n4. Imaging consistent with invasive pulmonary aspergillosis on CT or FDG-PET\u002FCT with lesions at least 8mm in diameter\n5. Patient is willing and able to comply with the protocol for the duration of the study including scheduled visits such as follow up\n\nExclusion Criteria:\n\n1. Women who are pregnant or lactating.\n2. Iron infusion within one week prior to scan",{"count":87,"type":21},"This trial will demonstrate localised uptake of a radiolabelled fungal component (siderophore) in areas of known specific invasive fungal (Aspergillus) infection.",[34],[34,116,117,118,119,120],"Siderophore","PET","Siderophore-labelled Position Emission tomography","68Ga-labelled TAFC PET\u002FCT scan","Aspergillus spp.","2025-08-28",{"date":123,"type":45},"2025-09-05",{"date":125,"type":45},"2023-12-01",{"date":127,"type":21},"2027-04",{"name":129,"class":52},"Peter MacCallum Cancer Centre, Australia",{"id":131,"slug":132,"hasResults":11,"nctId":133,"briefTitle":134,"officialTitle":135,"acronym":4,"eligibilityCriteria":136,"healthyVolunteers":11,"sex":16,"minAge":137,"maxAge":4,"enrollmentInfo":4,"targetDuration":4,"studyType":138,"phases":4,"briefSummary":136,"conditions":139,"keywords":140,"overallStatus":147,"whyStopped":4,"lastUpdateSubmitDate":148,"lastUpdatePostDateStruct":149,"startDateStruct":4,"completionDateStruct":4,"leadSponsor":151,"locationsCount":4},"100549370","expanded-access-to-fosmanogepix-for-patients-with-serious-or-life-threatening-invasive-fungal-infections-100549370","NCT06433128","Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections","Expanded Access to Fosmanogepix for Patients With Serious or Life-threatening Invasive Fungal Infections Who Have no Other Treatment Options","The EAP is intended to provide a treatment option for patients with proven or probable serious or life-threatening invasive fungal infection (in accordance with the EORTC-MSGERC criteria) who have exhausted their treatment options, primarily due to an infection with a resistant fungal pathogen, and for whom no other treatment options are available through marketed drugs or investigational agents in clinical studies ongoing in the respective indication.","12 Years","EXPANDED_ACCESS",[34],[141,142,143,144,145,146],"Fungal infection","Candida","Anti-fungal","Yeast","Mold","Rare mold","AVAILABLE","2025-07-23",{"date":150,"type":45},"2025-07-24",{"name":152,"class":153},"Basilea Pharmaceutica","INDUSTRY",{"id":155,"slug":156,"hasResults":11,"nctId":157,"briefTitle":158,"officialTitle":159,"acronym":160,"eligibilityCriteria":161,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":162,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":164,"conditions":165,"keywords":4,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":171,"lastUpdatePostDateStruct":172,"startDateStruct":174,"completionDateStruct":176,"leadSponsor":178,"locationsCount":53},"100557408","breath-analysis-for-the-detection-of-invasive-fungal-infections-100557408","NCT06537726","Breath Analysis for the Detection of Invasive Fungal Infections","Real-time Breath Analysis for the Detection of Invasive Fungal Infections in Neutropenic High-risk Patients","REDEFINE","Inclusion Criteria:\n\n* Diagnosis of acute leukemia\n* Planned chemotherapy with a duration of hospitalisation of 2 weeks or longer\n* Neutropenia (\\\u003C500\u002Fµl) present at inclusion or planned chemotherapy with expected neutropenia (\\\u003C500\u002Fµl) for more than 7 days\n\nExclusion Criteria:\n\n* Unable to follow instructions for breath analysis\n* Anatomic abnormalities precluding the use of a mouthpiece for breath analysis",{"count":163,"type":21},130,"Patients with leukemia and concomitant neutropenia are at high risk of developing invasive fungal infections (IFI) that are associated with high morbidity and mortality. As these patients typically have severe thrombocytopenia, direct diagnostic sampling with invasive procedures is often not possible due to the high peri-interventional risk. Therefore, the presumptive diagnosis of IFI is primarily based on compatible lung findings on computed tomography and serologic detection of fungal cell wall components, which, however, have limited sensitivity and specificity.\n\nWith the present study, the investigators aim to determine a set of specific volatile biomarkers in leukemia patients with proven or probable IFI using secondary electrospray ionization high-resolution mass spectrometry (SESI-HRMS).",[166,167,168,32,169,34,170],"Leukemia","Leukemia, Myeloid","Leukemia, Lymphoblastic","Chemotherapy-induced Neutropenia","Invasive Pulmonary Aspergillosis","2025-04-09",{"date":173,"type":45},"2025-04-10",{"date":175,"type":45},"2024-08-19",{"date":177,"type":21},"2027-10-31",{"name":179,"class":52},"University of Zurich",{"id":181,"slug":182,"hasResults":11,"nctId":183,"briefTitle":184,"officialTitle":184,"acronym":4,"eligibilityCriteria":185,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":186,"targetDuration":4,"studyType":187,"phases":188,"briefSummary":190,"conditions":191,"keywords":4,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":192,"lastUpdatePostDateStruct":193,"startDateStruct":195,"completionDateStruct":197,"leadSponsor":198,"locationsCount":53},"100574065","phase-4-population-pharmacokinetics-of-l-amb-in-chinese-patients-assisted-by-extracorporeal-membrane-pulmonary-oxygenation-ecmo-100574065","NCT06754436","Population Pharmacokinetics of L-AmB in Chinese Patients Assisted by Extracorporeal Membrane Pulmonary Oxygenation (ECMO)","Inclusion Criteria:\n\n* Diagnostic criteria for invasive fungal infections presenting to the intensive care unit (ICU) with probable or proved patients According to the 2021 EORTC\u002FMSGERC guideline.\n* Requiring ECOM assistance.\n* Age 18 years.\n\nExclusion Criteria:\n\n* Intolerance of L-AmB therapy.\n* Pregnancy.\n* Expected survival time \\\u003C24 hours.\n* Lack of necessary data on patient demographics physiopathology, and clinical status.",{"count":20,"type":21},"INTERVENTIONAL",[189],"PHASE4","The goal of this study is to investigate the effects of ECMO-assisted therapy on L-AmB PK parameters in patients with critically ill patients of invasive fungal infections, and to determine the in vivo pharmacokinetic changes of L-AmB in the ECMO population. To establish and validate a population pharmacokinetic model for liposomal amphotericin B in patients with critically ill patients of invasive fungal infections treated with ECMO adjuvant therapy, and to explore the pharmacokinetics\u002Fpharmacodynamics of the drug with different dosing regimens.",[34,36],"2024-12-30",{"date":194,"type":45},"2024-12-31",{"date":196,"type":21},"2025-01-10",{"date":75,"type":21},{"name":199,"class":52},"Beijing Anzhen Hospital",{"id":201,"slug":202,"hasResults":11,"nctId":203,"briefTitle":204,"officialTitle":205,"acronym":206,"eligibilityCriteria":207,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":208,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":210,"conditions":211,"keywords":212,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":217,"lastUpdatePostDateStruct":218,"startDateStruct":220,"completionDateStruct":222,"leadSponsor":224,"locationsCount":226},"100492165","usefulness-of-pet-ct-for-invasive-fungal-infection-100492165","NCT05688592","Usefulness of PET-CT for Invasive Fungal Infection","A Prospective Multicenter Study to Determine the Usefulness of Systematic 18-FDG-PET-TC for the Management of Invasive Fungal Infection (PETIFI Project)","PETIFI","Inclusion criteria:\n\n* 18-year-old adult patients\n* who are admitted with a diagnosis of invasive fungal infection\n* who able to undergo a one 18F-FDG PET-CT\n* who give their informed consent.\n\nExclusion criteria:\n\n* concomitant active bacterial infection likely to produce uptake in organs and tissues\n* recent surgery in the area of the IFI (in the previous 3 months)\n* other medical conditions that interfere with the development of the study ( e.g., inability to tolerate the performance of the test during the required time, pregnancy)\n* terminal situation.",{"count":209,"type":21},224,"The goal of this national multicenter prospective cohort study is to learn about the added value of 18F-FDG (18F-2-fluoro-2-deoxy-D-glucose) PET-CT in invasive fungal disease management. The main questions it aims to answer are:\n\n1. Does the use of 18F-FDG PET-CT allow a better characterization of invasive fungal infection (IFI) (performance) compared to the exclusive use of conventional radiological studies in terms of extension\u002Fstaging and monitoring of response\u002Ffollow-up ?\n2. Does the systematic and protocolized use of 18F-FDG PET-CT in IFI allow a better management of patients with IFI and increase the prognostic value of the initial evaluation? Participants will undergo systematically a 18F-FDG PET-CT as part of the work-up of their invasive fungal disease. Researchers will compare the performance of 18F-FDG PET-CT with standard management without 18F-FDG PET-CT to see if adds value (diagnostic, prognostic, and changes in management).",[34],[92,213,214,215,216],"PET-CT","management","staging","monitoring response","2024-11-04",{"date":219,"type":45},"2024-11-06",{"date":221,"type":45},"2023-04-27",{"date":223,"type":21},"2024-12-01",{"name":225,"class":52},"Puerta de Hierro University Hospital",14,{"id":228,"slug":229,"hasResults":11,"nctId":230,"briefTitle":231,"officialTitle":232,"acronym":233,"eligibilityCriteria":234,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":235,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":237,"conditions":238,"keywords":239,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":243,"lastUpdatePostDateStruct":244,"startDateStruct":246,"completionDateStruct":248,"leadSponsor":250,"locationsCount":53},"100554378","retrospective-study-of-invasive-fungal-infections-with-filamentous-fungi-in-heart-transplant-patients-100554378","NCT06498310","Retrospective Study of Invasive Fungal Infections With Filamentous Fungi in Heart Transplant Patients","Multicenter Retrospective Cohort Study on Invasive Fungal Infections With Filamentous Fungi in Heart Transplant Patients","IMI-CART","Inclusion Criteria:\n\n* Adult patient ≥18 years old\n* Heart transplant\n* Invasive fungal infection with filamentous fungi during the period from January 1, 2008 to December 31, 2022\n* Proven or probable infection with filamentous fungi according to EORTC\u002FMSGERC criteria (20):\n\n  * Invasive aspergillosis\n  * Mucormycosis\n  * Fusarium wilt\n  * Scedosporiosis\n  * Other filamentous fungus infection\n* Subject who has not expressed, after information, his opposition to the reuse of his data for the purposes of this research.\n\nExclusion Criteria:\n\n* Patient having expressed his opposition to participating in the study\n* Patient not having a liver transplant\n* Subject under guardianship, curatorship or safeguard of justice.",{"count":236,"type":21},100,"Invasive filamentous fungal infections (aspergillosis, scedosporiosis, mucormycosis, fusarium wilt) are common and serious in immunocompromised subjects and particularly organ transplant patients. There is little recent data in heart transplantation, particularly on the incidence and risk factors of fungal infections. . It is therefore important to have recent data on incidence, risk and prognostic factors in order to improve the management of this severe complication.",[34],[34,240,241,242],"Filamentous fungi","Heart transplant","Fungal infections","2024-07-04",{"date":245,"type":45},"2024-07-12",{"date":247,"type":45},"2023-11-08",{"date":249,"type":21},"2025-11-08",{"name":251,"class":52},"University Hospital, Strasbourg, France",{"id":253,"slug":254,"hasResults":11,"nctId":255,"briefTitle":256,"officialTitle":256,"acronym":257,"eligibilityCriteria":258,"healthyVolunteers":11,"sex":16,"minAge":17,"maxAge":4,"enrollmentInfo":259,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":261,"conditions":262,"keywords":268,"overallStatus":95,"whyStopped":4,"lastUpdateSubmitDate":272,"lastUpdatePostDateStruct":273,"startDateStruct":275,"completionDateStruct":277,"leadSponsor":279,"locationsCount":4},"100533019","path-study-people-with-injecting-related-infections-assessing-treatment-outcomes-for-those-who-are-hospitalised-100533019","NCT06220370","PATH Study: People With Injecting Related Infections: Assessing Treatment Outcomes for Those Who Are Hospitalised.","PATH","Inclusion Criteria:\n\n1. Have voluntarily signed the informed consent form,\n2. 18 years of age or older,\n3. Injected drugs within the last 6 months,\n4. Admitted to hospital with invasive bacterial or fungal infection, a. Examples of invasive infection include: bloodstream infection, bone and joint infection (osteomyelitis, septic arthritis, discitis), central nervous system infection (epidural abscess, meningitis), deep abscess (i.e., brain, liver, muscle, spleen), endovascular infection (infective endocarditis, septic thrombophlebitis, mycotic aneurysm, septic embolism), skin or soft tissue infection (necrotising fasciitis, myositis),\n\nExclusion Criteria:\n\n1\\) Is unable or unwilling to provide informed consent or abide by the requirements of the study.",{"count":260,"type":21},300,"We seek to characterise the burden and outcomes of and understand the current experience of people who inject drugs admitted to hospital with invasive injecting-related infections, in order to implement and evaluate strategies to improve completion of therapy and reduce patient-directed discharges, with ultimate benefit to the patient and health service.",[34,263,264,265,266,267],"Invasive Bacterial Infection","Injection Site Infection","Infection, Bacterial","Infection, Fungal","Infection, Soft Tissue",[269,270,271],"Antimicrobial therapy","Patient-directed discharge","Injection-related infectious diseases","2024-02-18",{"date":274,"type":45},"2024-02-20",{"date":276,"type":21},"2024-03-01",{"date":278,"type":21},"2029-03-01",{"name":280,"class":281},"Kirby Institute","OTHER_GOV",{"id":283,"slug":284,"hasResults":11,"nctId":285,"briefTitle":286,"officialTitle":287,"acronym":4,"eligibilityCriteria":288,"healthyVolunteers":11,"sex":16,"minAge":289,"maxAge":4,"enrollmentInfo":290,"targetDuration":4,"studyType":23,"phases":4,"briefSummary":292,"conditions":293,"keywords":294,"overallStatus":41,"whyStopped":4,"lastUpdateSubmitDate":298,"lastUpdatePostDateStruct":299,"startDateStruct":301,"completionDateStruct":303,"leadSponsor":305,"locationsCount":53},"100524024","fungal-surveillance-in-bangladesh-100524024","NCT06103331","Fungal Surveillance in Bangladesh","Surveillance for Invasive Fungal Infections in Selected Hospitals in Dhaka City, Bangladesh","Inclusion Criteria:\n\n* Inclusion criteria:\n\nMust include all of the following criteria:\n\n1. Admitted\u002Fhospitalized patients of any age and gender in tertiary-level acute care hospitals AND\n2. Having any of the following co-morbid immunosuppressive conditions or risk factors for healthcare-associated fungal infections such as:\n\n   * Chronic lung conditions including asthma, COPD\n   * Hemodialysis patients,\n   * diabetes,\n   * Patients receiving chemotherapy or immunosuppressive drugs (e.g. corticosteroids, immunosuppressive drugs among organ transplant recipients), for ≥7 days\n   * Patients with AIDS\n   * Patients at risk of healthcare-associated infections (e.g., Patients under postoperative care, having a urinary catheter, with tracheal intubation, under ventilatory support, secured with intravenous (IV) cannula, any other invasive procedures, etc.)\n   * Hospitalized Patients under prolonged injectable antibiotic treatment (\\>7 days)\n   * Prolonged hospitalization more than 7 days.\n   * History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization\n\n   AND\n3. Patients or caregivers providing consent\n\nFor children aged \\\u003C5 years, the age criteria and additional inclusion criteria will be as follows:\n\n* 0 to 59-month-old children of either sex admitted in hospital with any illness.\n* Have features of sepsis\u002Fpneumonia (based on clinical features below)\n\nAnd any of the following criteria:\n\n* Those who will fail to respond to injectable antibiotics or both 1st and 2nd line antibiotics (1st line- inj. Ampicillin plus gentamicin, 2nd line- inj. Ceftriaxone plus levofloxacin\u002Fgentamicin as per icddr,b hospital protocol)\n* Any child with SAM or h\u002Fo recent measles or any condition that may induce immune suppression plus fail to respond to injectable antibiotics\u002F 1st line antibiotics (1st line antibiotics- inj. Ampicillin +inj. Gentamicin)\n* Those who will develop late-onset hospital-associated infection (LOHAI)\n* Any child who will require ICU care for more than 7 days\n* Develop extensive thrush after taking long-term injectable antibiotics\n* History of taking steroids or antibiotics for more than 2 weeks prior to hospitalization\n\nExclusion Criteria:\n\n* History of taking antifungal drugs within 2 weeks\n* Not willing to give consent","0 Months",{"count":291,"type":21},800,"This will be an exploratory descriptive study designed to conduct surveillance for the identification of invasive fungal pathogens among hospitalized patients in Bangladesh at two tertiary care acute-level hospitals. including the Dhaka Medical College Hospital, the Dhaka Hospital of icddr,b, and the National Institute of Cancer Research Hospital (NICRH). Respiratory samples, blood, urine, cerebrospinal fluid, surgical wound infection swabs, and other samples including biopsy tissue specimens will be obtained at intensive care units, general medicine and surgery wards, post-operative care, etc. The collected specimens will be sent to the clinical microbiology laboratories of the surveillance hospitals or to the pathology laboratory (biopsy tissue specimens) to test for Aspergillus, Histoplasms, Candida, Pneumocystis, Cryptococcus, and Mucormycetes. The lab. methods will include microscopy, staining, culture, and biochemical tests mainly and if feasible then some specimens may undergo molecular or immunological methods.",[34],[295,296,297],"Invasive Fungal Pathogen","Hospitalized patients","Surveillance","2023-11-20",{"date":300,"type":45},"2023-11-22",{"date":302,"type":45},"2022-01-20",{"date":304,"type":21},"2026-09-30",{"name":306,"class":52},"International Centre for Diarrhoeal Disease Research, Bangladesh"]